TickerGuard
Buy Day today: Poor (44) Weak market breadth · today: Core PCE (August) ≈
RPRX

Royalty Pharma Plc

Healthcare · Biotechnology

57.70$ -1.5% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Cash Flow

Royalty Pharma Plc (RPRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at 686 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Cash Flow RPRX
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
574 773 665 658 704 743 596 364 703 827 761 686 2,976
0.0 0.0 – 4.6 -4.6 – 0.0 1.4 1.3 1.2 1.2 -1.2 2.5
0.6 0.6 0.6 0.7 0.5 0.5 0.5 91 73 126 122 107 428
-37 48 -29 50 -19 52 -64 50 -51 49 835 -1,670 -838
451 1,002 86 747 833 0.0 0.0 0.0 1.1 0.0 0.0 0.0 1.1
-451 -1,000 -87 -893 -1,193 -506 504 -312 -958 -848 -520 -187 -2,514
90 89 94 95 94 94 95 93 95 94 104 105 399
-140 -30 0.0 -80 -97 -53 -709 -292 -146 -81 -50 -45 -322
– – – – 0.0 0.0 – – 954 0.0 – – –
-1,359 -232 -212 1,157 -326 -258 -941 -508 563 -300 -273 -273 -283
-1,237 -459 366 922 -815 -21 159 -456 307 -320 -32 226 180
574 773 665 658 704 743 596 364 703 827 761 686 2,976

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?